<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="134557">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01988779</url>
  </required_header>
  <id_info>
    <org_study_id>45566</org_study_id>
    <nct_id>NCT01988779</nct_id>
  </id_info>
  <brief_title>Oral Versus Topical Antibiotics for Chronic Rhinosinusitis Exacerbations</brief_title>
  <official_title>Oral Versus Topical Antibiotic Therapy for Treatment of Chronic Rhinosinusitis Exacerbations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to treat patients with a diagnosis of chronic rhinosinusitis
      (CRS) and a history of bilateral endoscopic sinus surgery during times of worsening symptoms
      and signs of acute infection on nasal endoscopy with one of two treatments: (1) oral
      antibiotics and twice daily intranasal saline irrigations or (2) oral placebo and twice
      daily intranasal antibiotic irrigations. The two treatments will be compared to see if there
      is any difference in patient outcomes. This will help guide treatment strategies for
      patients with CRS in the future.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      See brief summary.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in Rhinosinusitis Disability Index (RSDI) scores</measure>
    <time_frame>14 days after treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endoscopy findings using POSE scores</measure>
    <time_frame>14 days after treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the total bacterial community following treatment as determined by RNA pyrosequencing.</measure>
    <time_frame>14 days after treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in aerobic bacterial cultures performed via traditional microbiology plating techniques</measure>
    <time_frame>14 days after treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Chronic Rhinosinusitis</condition>
  <arm_group>
    <arm_group_label>oral placebo with nebulized intranasal levofloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo oral tablet by mouth daily for 14 consecutive days along with nebulized levofloxacin 125 mg twice daily for 14 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oral antibiotics with nebulized intranasal placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Levofloxacin 500 mg by mouth once daily for 14 consecutive days, along with intranasal placebo solution twice daily for 14 consecutive days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral levofloxacin</intervention_name>
    <arm_group_label>oral placebo with nebulized intranasal levofloxacin</arm_group_label>
    <arm_group_label>oral antibiotics with nebulized intranasal placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nebulized levofloxacin</intervention_name>
    <arm_group_label>oral placebo with nebulized intranasal levofloxacin</arm_group_label>
    <arm_group_label>oral antibiotics with nebulized intranasal placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adults (age â‰¥ 18).

          2. Diagnosis of CRS.

          3. Worsening sinonasal symptoms.

          4. Previous bilateral endoscopic sinus surgery (ESS) (including maxillary antrostomy and
             anterior ethmoidectomy).

          5. English speaking.

          6. Open sinuses (open middle meatus bilaterally; determined on endoscopy).

          7. Positive sinonasal culture (1+ or greater) with sensitivity to one of the pre-chosen
             antibiotic regimens.

        Exclusion Criteria:

          1. Patients &lt; 18 years of age.

          2. Treatment with systemic or topical antibiotics within the last 1 month.

          3. Pregnant women.

          4. Non-English speaking persons.

          5. Systemically ill at initial visit necessitating treatment prior to culture data.

          6. Allergies to chosen susceptible antibiotics.

          7. Sinonasal culture with less than 1+ growth.

          8. Multiple organisms grown on culture that are not sensitive to a single antibiotic.

          9. Patients with ciliary function disorders (cystic fibrosis, Kartagener's syndrome,
             ciliary dyskinesia).

         10. Patients with immunodeficiencies.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li-Xing Man, MD, MPA, Msc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexis Strohl, MD</last_name>
    <phone>585-758-5700</phone>
    <email>Alexis_Strohl@urmc.rochester.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Rochester Department of Otolaryngology Head and Neck Surgery</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alexis Strohl, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Li-Xing Man, MSc, MD, MPA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 2, 2013</lastchanged_date>
  <firstreceived_date>November 13, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Li-Xing Man</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sinusitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
